Efficacy of oral consumption of curcumin/Curcuma longa for symptom improvement in inflammatory bowel disease:A systematic review of animal models and a meta-analysis of randomized clinical trials  

作　　者：MARLA DE CERQUEIRA ALVES MONISE OLIVEIRA SANTOS NASSIB BEZERRA BUENO ORLANDO ROBERTO PIMENTEL DE ARAúJO MARíLIA OLIVEIRA FONSECA GOULART FABIANA ANDRéA MOURA 

机构地区：[1]Programa de Pós-Graduacao em Nutricao(PPGNUT),Universidade Federal de Alagoas(UFAL),Maceió,AL 57072-970,Brazil [2]Instituto de Química e Biotecnologia(IQB),Universidade Federal de Alagoas(UFAL),Maceió,AL 57072-970,Brazil [3]Programa de Pós-Gradua玢o em Ciências da Saúde(PPGCS),Universidade Federal de Alagoas(UFAL),Maceió,AL 57072-970,Brazil [4]Programa de Pós-Gradua玢o da Rede Nordeste de Biotecnologia(RENORBIO),Universidade Federal de Alagoas(UFAL),Maceió,AL 57072-970,Brazil [5]Programa de Pós-Gradua玢o em Ciências Médicas(PPGCM),Universidade Federal de Alagoas(UFAL),Maceió,AL 57072-970,Brazil

出　　处：《BIOCELL》2022年第9期2015-2047,共33页生物细胞（英文）

基　　金：This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico(CNPq–Brazil)[Grant No.435704/2018-4];Fundacao de AmparoàPesquisa do Estado de Alagoas(FAPEAL)/PPSUS/Ministério da Saúde(MS)[Grant No.60030-000876/2016].

摘　　要：The roots of the vegetal Curcuma due to its high content of polyphenols,has been used successfully in several clinical situations.This review assessed the effect of curcumin/Curcuma longa on symptoms and metabolic changes in inflammatory bowel disease(IBD).A systematic review of animal models and randomized clinical trials(RCTs)was conducted by searching the following electronic databases:PubMed,CENTRAL,LILACS,Science Direct,and ClinicalTrials.gov.From 997 found records,62 were included.More than 90%of the animal studies reported an improvement in macroscopic,histologic and/or functional activity;80%identified decreased oxidative and/or inflammatory biomarkers in animals treated with curcumin.Among the RCTs,intention-to-treat analysis showed that oral curcumin was effective in inducing clinical remission(n=281,RR:3.15 CI 95%[1.22–8.10]p=0.0017;i2=72.2%,p=0.006)and clinical response(n=259,RR:1.60 CI 95%[1.09–2.35]p=0.0017;i2=59.7%,p=0.042)but not endoscopic remission(n=161,RR:2.91 CI 95%[0.58–14.58]p=0.195;i2=72.7%,p=0.026).These results confirm that oral supplementation with curcumin/Curcuma longa has beneficial actions in animal colitis and,when associated with drug therapy,is effective in the treatment of patients with IBD.

关 键 词：Ulcerative colitis Crohn’s disease Oxidative stress CURCUMA Turmeric 

分 类 号：R57[医药卫生—消化系统]